Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.
Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.
CEO, Synairgen plc
Talk to the deal team
Fine Mito Srl has acquired Cover 50 SpA
Fine Mito Srl has acquired 21.4% of Cover 50 SpA through a voluntary public tender offer.Learn more
Nebula Aurea Bidco SpA has acquired Reevo SpA
Nebula Aurea BidCo SpA has acquired 100% of the shares and warrants of Reevo SpA by a total voluntary public tender offer.Learn more
Sicily by Car SpA has been listed on Euronext Growth Milan
Sicily by Car SpA has been listed on the Euronext Growth Milan market after the business combination with the SPAC Industrial Stars of Italy 4, for a total deal value of US$109.5 million.Learn more